ArticleNature communications2022
Expanding cross-presenting dendritic cells enhances oncolytic virotherapy and is critical for long-term anti-tumor immunity.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
10.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 65 citations in OpenAlex.
- Opportunities and challenges for cancer immunotherapy based on antigen cross-presentation.Annals of medicine · 2026Review
- Oncolytic virus-delivered GSDME: Unlocking pyroptosis to improve dendritic cell function and amplify cytotoxic T cell response.Molecular therapy. Oncology · 2026Article
- Beyond cold to hot: oncolytic virotherapy as the next cornerstone of immuno-oncology.Nature reviews. Clinical oncology · 2026Review
- Review
- Neoantigen-Encoded Oncolytic Viruses as Personalized Cancer Vaccines.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Oncolytic viruses: advanced strategies in cancer therapy.Signal transduction and targeted therapy · 2026Review
- Research progress on immune tolerance mechanisms in liver metastatic tumors and the "Liver-metastasis-oriented shared-mechanism therapeutic strategy" approach.Medical review (2021) · 2026Review
- Fusion protein-mediated costimulation in engineered T cells: from intrinsic signaling to tumor microenvironment rewiring.Frontiers in immunology · 2026Review
- Review
- Advances in neoadjuvant immunotherapy for non-small cell lung cancer.Frontiers in immunology · 2026Review
- Intratumoral delivery of FLT3L with CXCR3/CCR5 ligands promotes XCR1Nature communications · 2025Article
- Engineering the tumor microenvironment: oncolytic NDV to facilitate CAR-T cell therapy.Journal of translational medicine · 2025Review
- Oncolytic virus-induced IL-1βJournal for immunotherapy of cancer · 2025Article
- Cryogel-Based Dendritic Cell Immunotherapy for Post-Surgical Breast Cancer Treatment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Oncolytic HSV-1 expressing FLT3L kills melanoma, glioblastoma, and pancreatic cancer cellsMolecular therapy. Oncology · 2025Article
- Engineered T cells stimulate dendritic cell recruitment and antigen spreading for potent anti-tumor immunity.Cell reports. Medicine · 2025Article
- Targeting the CD40 costimulatory receptor to improve virotherapy efficacy in diffuse midline gliomas.Cell reports. Medicine · 2025Article
- Oncolytic immunovirotherapy: finding the tumor antigen needle in the antiviral haystack.Immunotherapy · 2025Review
- Review
- Single-cell data-driven design of armed oncolytic virus to boost cooperative innate-adaptive immunity against cancer.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 5 institutions in 3 countries.
Judit Svensson-ArvelundHematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA. judit.arvelund@liu.se.ORCID 0000-0002-6260-0808
Sara Cuadrado-CastanoDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.ORCID 0000-0002-9400-746X
Gvantsa PantsulaiaHematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.ORCID 0000-0002-1137-7538
Kristy KimHematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.ORCID 0000-0002-3869-4939
Mark AleynickHematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
Linda HammerichHematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.ORCID 0000-0003-0557-3927
Ranjan UpadhyayHematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.ORCID 0000-0002-1326-5898
Michael YellinCelldex Therapeutics, Inc, Needham, MA, 02494, USA.
Henry MarshCelldex Therapeutics, Inc, Needham, MA, 02494, USA.
Daniel OreperGenentech, South San Francisco, CA, 94080, USA.
Suchit JhunjhunwalaGenentech, South San Francisco, CA, 94080, USA.
Christine MoussionGenentech, South San Francisco, CA, 94080, USA.
Miriam MeradTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.ORCID 0000-0002-4481-7827
Brian D BrownTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.ORCID 0000-0002-3670-8778
Adolfo García-SastreTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.ORCID 0000-0002-6551-1827
Joshua D BrodyHematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA. joshua.brody@mssm.edu.ORCID 0000-0002-0850-6730
Icahn School of Medicine at Mount Sinai · USCelldex Therapeutics (United States) · USCharité - Universitätsmedizin Berlin · DELinköping University · SETisch Hospital · US
Funding
Investigating Macrophage Molecular and Functional Diversity in Tumor ImmunityR01CA254104 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BROWN, BRIAN D, MERAD, MIRIAM · 2021 to 2025
$3.4MDissecting the pathways driving progenitor to pro-tumor macrophage programmingR01CA257195 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Brian D Brown, MIRIAM MERAD · 2021 to 2026
$3.3MEarly development of small molecule dendritic cell immunopotentiators for the treatment of solid tumorsR01CA229818 · NCI · SCRIPPS RESEARCH INSTITUTE, THE · PI CHANDA, SUMIT K, GARCIA-SASTRE, ADOLFO · 2018 to 2021
$2.9MPotentiating Checkpoint Blockade by Cross-Priming Tumor-Reactive T cells with In Situ VaccinationR37CA246239 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Joshua D Brody · 2020 to 2026
$2.6MNCI NIH HHS R01 CA229818NCI NIH HHS R01 CA254104NCI NIH HHS R01 CA257195NCI NIH HHS R37 CA246239
Abstract
Immunotherapies directly enhancing anti-tumor CD8
Indexed as
NeoplasmsOncolytic VirotherapyVaccinesAnimalsAntigens, NeoplasmCD8-Positive T-LymphocytesCross-PrimingDendritic CellsAntigens, NeoplasmVaccines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.